Gary Gordon

The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis

Gideon Steinbach, Patrick M. Lynch, Robin Phillips et al. · New England Journal of Medicine · 2000 · 2.5K citations · Full text

Celecoxib for the Prevention of Sporadic Colorectal Adenomas

Monica M. Bertagnolli, Craig Eagle, Ann G. Zauber et al. · New England Journal of Medicine · 2006 · 1K citations · Full text

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig et al. · The Lancet Oncology · 2016 · 783 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +7

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al. · Journal of Clinical Oncology · 2017 · 737 citations · Full text

Immunology, Pathology, Pharmacotherapy +17

Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis

Susan M. Fischer, Herng-Hsang Lo, Gary Gordon et al. · Molecular Carcinogenesis · 1999 · 404 citations

Chemoprevention Strategy, Chemopreventive Activity, Medicine +12